Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2022-11-15
2024-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
OBJECTIVE: To describe the incidence of TE events in patients with AN compared to the background population, to characterize the hemostatic balance in AN compared to normal-weight women, and to assess the associations between the hemostatic balance and nutritional status, insulin sensitivity and cortisol level in women with AN.
METHODS: The incidence of TE will be described using a Danish cohort of AN patients (n=10,049) with follow-up in national registries. A comprehensive battery of hemostatic biomarkers will be compared in a case-control study of 40 patients with AN and associations between hemostasis and nutritional status will be studied.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa
NCT00310791
The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa
NCT00853502
Hormonal Factors in the Treatment of Anorexia Nervosa
NCT01121211
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
NCT02994602
Phlebotomy Study of Testosterone Undecanoate
NCT02670343
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Anorexia nervosa (AN) is a complex psychiatric disorder with concomitant medical complications to malnutrition and starvation and it is associated with the highest mortality of the mental illnesses.
It is estimated that one-third of all deaths in patients with AN are due to cardiac causes, mainly sudden death, and alterations in cardiac electrical activity, structure and hemodynamics have been suggested as mortality causes. Thrombotic disorders such as myocardial infarction, stroke, and pulmonary embolism may also result in sudden cardiac death, and the investigators have previously reported venous thromboembolism in four patients with AN
Whether a disturbed hemostatic balance is associated with re-nutrition, insulin sensitivity and cortisol in AN is unknown. The guidelines of thromboprophylaxis treatment may not be appropriate in this patient group due to metabolic and hemostatic disturbances and increased thrombotic risk of reasons related to refeeding syndrome not listed in current guidelines. To optimize guidelines for AN patients, new evidence is highly warranted
AIMS
This study aims to determine the incidence of venous and arterial thromboembolic events in patients with AN compared to the background population, to characterize the hemostatic balance in AN compared to normal-weight women, and to assess the associations between the hemostatic balance and nutritional status, insulin sensitivity and cortisol level in women with AN. The study will provide new knowledge which qualifies the work of preparing guidelines for thrombosis prophylactic intervention in this patient group.
RESEARCH QUESTIONS
1. Is the incidence of venous and arterial thromboembolism increased in patients diagnosed with AN compared to an age-matched control group?
2. Is the hemostatic balance disturbed in women with AN compared with healthy, normal-weight women?
3. Are cortisol, insulin sensitivity and nutritional status associated with alterations in biomarkers of the hemostatic balance in AN?
The research questions will be answered in three sub studies.
SUB STUDY 1
Sub study 1 will answer research question 1, determining if the incidence of venous and arterial thromboembolism is increased in patients with AN compared to an age-matched control group. The study is based on the comprehensive Danish registries. An already existing cohort of more than 10,000 patients with AN will be evaluated for incidence of thromboembolic events and compared to an age-matched control group.
SUB STUDY 2
Sub study 2 will answer research question 2, exploring the hemostatic balance in patients with AN compared to healthy, normal-weight controls.
Patients with anorexia nervosa (n=40) will be recruited from the highly specialized Center of Eating Disorders at Odense University Hospital. Patients and controls will have blood samples drawn to evaluate the hemostatic balance using a large battery of hemostatic markers.
SUB STUDY 3
Sub study 3 will answer research question 3, clarifying associations between the hemostatic balance and cortisol, insulin sensitivity and nutritional status in AN. Participants of sub study 3 are the patients with AN from sub study 2. From further analysis of the blood samples and by answering validated questionnaires to determine nutritional status and AN severity, research question 3 will be answered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
Blood samples
Hemostatic biomarkers
Questionnaires
Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
Controls
Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
Blood samples
Hemostatic biomarkers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Hemostatic biomarkers
Questionnaires
Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 - 50 years
* Female sex
* BMI 18.5 - 25.0
* Age 18 - 50 years
* Female sex
Exclusion Criteria
* Previous thromboembolic event and/or known genetic predisposition
* Use of p.o. hormonal contraception
* Smoking
* Somatic comorbidity requiring systemic medications
* Previous thromboembolic event and/or known genetic predisposition
* Use of p.o. hormonal contraception
* Smoking
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeanie Meincke Egedal, MD
Medical Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Pharmacology and Pharmacy, University of Southern Denmark
Odense, Fyn, Denmark
Department of Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark
Odense, Fyn, Denmark
The Nutritional Unit, Department of Endocrinology, Center for Eating Disorders, Odense University Hospital and Psychiatry in the region of Southern Denmark
Odense, Fyn, Denmark
Unit for Thrombosis Research, Department of Clinical Biochemistry, Hospital of South West Jutland
Esbjerg, Jylland, Denmark
Department of Clinical Sciences, Umeå University
Umeå, Västerbotten County, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
85860
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.